# A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects

> **NCT06014853** · PHASE1 · COMPLETED · sponsor: **Bukwang Pharmaceutical** · enrollment: 48 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** SOL-804-F
- **DRUG:** Zytiga

## Key facts

- **NCT ID:** NCT06014853
- **Lead sponsor:** Bukwang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-10
- **Primary completion:** 2023-10-28
- **Final completion:** 2023-11-16
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06014853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06014853, "A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06014853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*